<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027538" disease_type="Disease or Syndrome" abbrv="">Necrobiosis lipoidica</z:e> (NL) is a <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disease</z:e> that is difficult to treat </plain></SENT>
<SENT sid="1" pm="."><plain>The etiology is unknown, but <z:hpo ids='HP_0002597'>vascular abnormalities</z:hpo> and immunologic factors have been implicated </plain></SENT>
<SENT sid="2" pm="."><plain>We treated a patient with long-standing NL with multiple vascular risk factors (<z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S-deficiency</z:e>, and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>) with topical tacrolimus, a non-steroidal immunomodulator that causes no <z:hpo ids='HP_0004334'>skin atrophy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>After 12 weeks of topical tacrolimus (0.1%) ointment, our patient already showed a good remission with a significant decrease in inflammatory signs </plain></SENT>
</text></document>